Khiron Life Sciences Corp.
Other OTCTotal Valuation
Khiron Life Sciences Corp. carries a market capitalization of 2,324.00, placing it among publicly traded companies globally. Its enterprise value stands at 20.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2,324.00 |
| Enterprise Value | 20.04M |
Share Statistics
Khiron Life Sciences Corp. currently has 217.14M shares outstanding.
| Shares Outstanding | 217.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.20, and the price-to-book ratio stands at 0.81.
| PE Ratio | N/A |
| PS Ratio | 1.20 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | -1.58 |
| P/OCF Ratio | -1.29 |
Enterprise Valuation
| EV / Sales | 1.24 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Khiron Life Sciences Corp. maintains a current ratio of 1.91, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.46, indicating elevated leverage, while an interest coverage ratio of -52.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.91 |
| Quick Ratio | 0.67 |
| Debt / Equity | 9.46 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | -52.35 |
Financial Efficiency
| Return on Equity (ROE) | -84.09 |
| Return on Assets (ROA) | -58.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.96 |
Taxes
| Income Tax | -367,917.00 |
| Effective Tax Rate | N/A |
Income Statement
Over the trailing twelve months, Khiron Life Sciences Corp. generated 16.14M in revenue and converted that into -30.66M in net income, yielding earnings per share of -0.16. EBITDA reached -14.71M, while operating income came in at -16.67M.
| Revenue | 16.14M |
| Gross Profit | 6.67M |
| Operating Income | -16.67M |
| Pretax Income | -31.03M |
| Net Income | -30.66M |
| EBITDA | -14.71M |
| EBIT | -16.67M |
| Earnings Per Share (EPS) | -0.16 |
Balance Sheet
Khiron Life Sciences Corp. holds 1.94M in cash and equivalents against 2.56M in total debt, resulting in a net debt position of -484,000.00. Total book value stands at 23.90M, with working capital of 8.72M providing operational flexibility.
| Cash & Cash Equivalents | 1.94M |
| Total Debt | 2.56M |
| Net Debt | -484,000.00 |
| Equity (Book Value) | 23.90M |
| Book Value Per Share | 0.12 |
| Working Capital | 8.72M |
Cash Flow
Khiron Life Sciences Corp. produced -15.01M in operating cash flow over the past twelve months. After subtracting -2.73M in capital expenditures, free cash flow totaled -17.74M - equivalent to -0.09 per share.
| Operating Cash Flow | -15.01M |
| Capital Expenditures | -2.73M |
| Free Cash Flow | -17.74M |
| FCF Per Share | -0.09 |
Margins
Khiron Life Sciences Corp. operates with a gross margin of 41.34, reflecting its pricing power and cost economics. The operating margin of -103.27 and net profit margin of -190.00 provide insight into operational efficiency.
| Gross Margin | 41.34 |
| Operating Margin | -103.27 |
| Pretax Margin | -192.28 |
| Profit Margin | -190.00 |
| EBITDA Margin | -91.15 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -24.47 |
| FCF Yield | -63.28 |
Scores
Khiron Life Sciences Corp. posts an Altman Z-Score of -5.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.57 |